<DOC>
	<DOCNO>NCT02922816</DOCNO>
	<brief_summary>Transplant patient increase risk colonization infection Multidrug Resistant Organisms ( MDROs ) due medication modify immune system , increase healthcare antibiotic exposure , surgical manipulation mucosa . In study , kidney transplant patient infection resistant bacteria give Fecal Microbiota Transplant ( FMT ) , also know fecal transplant , receive antibiotic treatment . This study see FMT eliminate resistant bacteria kidney transplant patient use last resort antibiotic . This Phase 1 pilot study obtain preliminary safety data FMT renal transplant patient support rationale subsequent clinical trial , establish efficacy toxicity . This trial design test safety FMT , identify clinical outcome , assess feasibility , refine target population participant MDRO colonization intestinal dysbiosis . Data study provide direction design future clinical trial .</brief_summary>
	<brief_title>FMT MDRO Colonization After Infection Renal Transplant Recipients</brief_title>
	<detailed_description>Potential participant meet key eligibility criterion [ adult undergone renal transplantation history infection Target Multidrug Resistant Organisms ( MDRO ) ] approach consideration study participation . For study , Target MDRO colonization define positive bacterial culture either carbapenem-resistant Enterobacteriaceae ( CRE ) , vancomycin-resistant Enterococcus ( VRE ) , Extended Spectrum Beta-Lactamases ( ESBL ) , and/or multidrug resistant ( MDR ) Pseudomonas perirectal swab sampling . The 20 trial participant randomize 1:1 ratio one two arm : control arm [ receive Allogeneic Human Stool Glycerol ( 10 % ; AHSG ) via Fecal Microbiota Transplant ( FMT ) ] experimental arm ( receive AHSG via FMT ) . Participants control arm participant crossover receive treatment complete study cycle without FMT . Each cycle last 6 week participant complete maximum 2 treatment cycle ; participant randomize experimental arm complete maximum two cycle randomize control arm complete three cycle . Upon completion final cycle , trial participant follow 6 month . In addition trial participant , also one stool donor participant . The consented , screen , eligible stool donor identify establish group stool donor undergo screen procedure specific study . This individual donate human stool preparation AHSG ( know IND product study ) . Upon process AHSG , stool donor enter Follow-Up Period remain available communication study team ( necessary ) Study Completion Date . However , schedule study assessment require stool donor .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Ability understand willingness sign write informed consent document . Ability willingness comply study protocol requirement receive IND product via rectal retention enema , manufacture preselected stool donor participant . History MDRO infection least one follow Target MDROs : CRE , VRE , ESBL , MDR Pseudomonas . Not systemic antibiotic reason MDRO infection recent potential participant still take antibiotic target MDRO time screen . If latter , participant must complete antibiotic course Study Day 2 Periectal swab sample positive Target MDRO ( e.g CRE , VRE , ESBL , and/or MDR Pseudomonas ) result within two week prior enrollment , confirm Clinical Laboratory Improvement Amendments ( CLIA ) certify laboratory . Prior receipt living decease donor renal transplant . Performance status either : American Society Anesthesiology ( ASA ) Classification Score IIII , Eastern Cooperative Oncology Group ( ECOG ) performance status score 02 , Karnofsky Performance Score ( KPS ) 50100 % . At least one prior course systemic antibiotic since renal transplant . If applicable , willingness discontinue probiotic microbiota restoration therapy screen least seven day prior first intervention . The effect FMT develop human fetus unknown . For reason , woman childbearing potential ( WOCBP ) men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Negative blood urine human chorionic gonadotropin ( hCG ) test day FMT WOCBP documentation negative test result Negative HIV test ( HIV 1/2 antibody ) last 30 day Known screening drug monitoring level ( e.g. , tacrolimus ) ; subject screening window Known serology CMV status confirm either Medical History ( positive ) . If mention positivity medical record , serology test within 30 day enrollment : 1 . Cytomegalovirus ( CMV ) polymerase chain reaction ( PCR ) 2 . Cytomegalovirus ( CMV ) , serology Immunoglobulin G ( IgG ) Female participant pregnant , breastfeeding , lactate , plan pregnancy study duration ( 4 week last dose IND product ) . Prior gastrointestinal surgery intervention : 1 . Ileostomy ( last 3 month ) 2 . Colostomy ( last 3 month ) 3 . Gastric colon resection ( last 3 month ) 4 . Bariatric surgery ( prior history ) 5 . Total colectomy ( prior history ) Any follow gastrointestinal condition : 1 . Irritable Bowel Syndrome ( IBS ) diarrhea last 12 month 2 . Crohn 's disease 3 . Ulcerative Colitis 4 . Celiac disease 5 . Untreated insitu colorectal cancer 6 . Microscopic ulcerative colitis 7 . Toxic megacolon ileus 8 . Tube feeding ( current plan ) Known positive stool study culture last 30 day : 1 . Ova 2 . Parasites 3 . Salmonella 4 . Shigella 5 . Campylobacter 6 . Clostridium difficile ( enteropathogen ) test Xpert C. difficile platform 7 . Other enteropathogens define positive result Biofire FilmArray Gastrointestinal Panel , ( Campylobacter , Plesiomonas , Salmonella , Vibrio , Yersinia , Enteroaggregative Escherichia coli ( EAEC ) , Enteropathogenic Escherichia coli ( EPEC ) , Enterotoxigenic Escherichia coli ( ETEC ) , Shigella , Cryptosporidium , Cyclospora , Entamoeba , Giardia , Adenovirus , Astrovirus , Norovirus , Rotavirus , Sapovirus ) . Known uncontrolled intercurrent illness ( e ) , limit : 1 . Ongoing active infection 2 . Symptomatic congestive heart failure 3 . Unstable angina pectoris 4 . Cardiac arrhythmia 5 . Any intercurrent acute illness opinion investigator preclude subject enter study Compromised immune system transplant immunosuppression : 1 . HIVpositive identify one following : 1 . Positive HIV 1/2 antibody test result 2 . Positive HIV p24 antigen test result 3 . Prior diagnosis HIV 4 . Active history administration combination antiretroviral therapy ( cART ) 2 . Known absolute neutrophil count ( ANC ) &lt; 1000 neutrophils/mm^3 3 . Active malignancy require intensive induction chemotherapy , radiotherapy , biologic treatment either concurrently last 2 month 4 . Acute leukemia 5 . History bone marrow transplantation ( allogeneic autologous ) last 3 year History organ transplant rejection last 6 month Significant food allergy food part stool donor participant 's diet . Life expectancy 24 week less . Any condition , opinion investigator , might interfere study objective limit compliance study requirement , include limited : 1 . Known active intravenous drug alcohol abuse 2 . Psychiatric illness 3 . Social situation Participated investigational study also meet one follow criterion : 1 . Received interventional agent ( drug , device , procedure ) last 28 day 2 . Enrollment study interventional study MDROs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Carbapenem-resistant Enterobacteriaceae ( CRE )</keyword>
	<keyword>Vancomycin-resistant Enterococcus ( VRE )</keyword>
	<keyword>Multidrug Resistant Organism ( MDRO )</keyword>
	<keyword>Fecal Microbiota Transplant ( FMT )</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Colonization</keyword>
	<keyword>Infection</keyword>
	<keyword>Antibiotic Resistance</keyword>
	<keyword>Resistome</keyword>
	<keyword>Multidrug Resistant ( MDR ) Pseudomonas</keyword>
</DOC>